Thermo Fisher Scientific Features ImmunoCAP Tryptase Assay at AACC 2012
Tryptase is one of the World Health Association criteria that is used for making a diagnosis of systemic mastocytosis, and with today’s clearance, laboratories throughout the U.S. can now offer tryptase testing to their customers on fully automated CLIA Moderate Complexity instruments
Tuesday, July 17, 2012 2:45 pm EDT
 

Dateline:

LOS ANGELES, Calif.

LOS ANGELES, Calif. (July 17, 2012 )--Thermo Fisher Scientific Inc., the world leader in serving science, is featuring the Thermo Scientific ImmunoCAP Tryptase Assay at the 2012 annual conference of the American Association for Clinical Chemistry (AACC). ImmunoCAP Tryptase is the first commercially available assay in the U.S. for mast cell tryptase to be available on Clinical Laboratory Improvement Amendments (CLIA) Moderate Complexity fully automated laboratory instruments. ImmunoCAP Tryptase is cleared for use with the Phadia® 100, Phadia 250, and Phadia 1000 instruments and is being featured within Thermo Scientific booth #2215 during AACC, at the Los Angeles Convention Center from July 17-19.

ImmunoCAP Tryptase measures the level of tryptase in serum/plasma. Human tryptase is present in mast cells, and serum/plasma basal levels of tryptase give an indication of number of mast cells. Elevated basal levels of tryptase are an indicator of systemic mastocytosis.

Systemic mastocytosis is a severe chronic disease with an increased number of mast cells in the skin and other tissues and organs. It is not possible to diagnose systemic mastocytosis based solely on physical examination. Having received 510(k) clearance from the U.S. Food and Drug Administration in February, the ImmunoCAP Tryptase provides physicians with additional tools and clinical insight to make an accurate diagnosis.

 “Tryptase is one of the World Health Association criteria that is used for making a diagnosis of systemic mastocytosis, and with today’s clearance, laboratories throughout the U.S. can now offer tryptase testing to their customers on fully automated CLIA Moderate Complexity instruments,” said Jean Forcione, president of Thermo Fisher’s immunodiagnostics business.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. With revenues of $12 billion, we have approximately 39,000 employees and serve customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as in environmental and process control industries. We create value for our key stakeholders through three premier brands, Thermo Scientific, Fisher Scientific and Unity™ Lab Services, which offer a unique combination of innovative technologies, convenient purchasing options and a single solution for laboratory operations management. Our products and services help our customers solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Visit www.thermofisher.com.

Contact:

Aaron Kellogg
617-275-6526
akellogg@greenough.biz